Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Abstract

Mycobacterium bovis BCG is attenuated strain derived from M. bovis. It has been known to prevent childhood pulmonary and meningeal tuberculosis and to treat superficial bladder cancer as immunotherapy. Administration of BCG has been restricted to immune-deficient individuals since 2007 because of its combined complications. Which treated with antituberculosis drugs based on assumption is fully responsive to these drugs. BCG Connaught showed more susceptibility to the activity of isoniazid, ethambutol, kanamycin, ofloxacin, streptomycin, amikacin and capreomycin than BCG Pasteur growing in J774A.1 cells. While the activity of rifampicin and levofloxacin was the same between the two tested strains. The spectrum of intracellular drug action can be ordered based on a decreasing order of inhibitory activity, as following rifampin > isoniazid > ethambutol > streptomycin > kanamycin> amikacin> ofloxacin> capreomycin> levofloxacin against BCG Connaught. While rifampin > isoniazid > ethambutol > kanamycin = streptomycin > ofloxacin> amikacin> levofloxacin> capreomycin for BCG Pasteur. There is a very limited publications describe the activity of antituberculosis drugs against intracellular growing BCG strains.